肺癌血清相关肿瘤标志物的研究进展

Research progress of serum tumor markers assciated with lung cancer

从临床治疗角度出发,结合生物学特性可将肺癌分为两大类:小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC)。小细胞肺癌主要表现为神经内分泌特性,恶性程度高,生长快,较早出现淋巴转移和血行播撒,对化疗和放疗敏感。大多数非小细胞肺癌缺乏神经内分泌特性,组织学上包括腺癌(AD,40%),鳞癌(SQC,30%)、大细胞癌(10%)等类型,对放疗和化疗的敏感性明显低于小细胞肺癌。血清中神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(Pro GRP)、细胞角蛋白19片段(Cyfra21-1)、鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)水平与肺癌的进展、分期及诊断密切相关,本文旨在探讨五种肿瘤标志物在肺癌诊断中的应用价值。

From the perspective of bed treatment,lung cancer can be divided into two major groups according to its biological characteristics：small lung cancer and non-small lung cancer.Small cell lung cancer mainly presents neuroendocrine characteristics,high degree of malignancy,rapid growth,early lymphatic metastasis and blood seeding,sensitive to chemotherapy and radiotherapy.Most non-small-cell lung cancer lack of neuroendocrine features histologically including Adenocarcinoma （40 % ）,squamous cell carcinomas（30 % ）,large cell carcinoma（10 % ）,and other types,their sensitivity to radiotherapy and chemotherapy significantly lower than the small cell lung cancer.The serum level of Neuronal specific enolase、pro-gastrin releasing peptide、cytokeratin 19 Fragment、squamous cell carcinoma antigen、carcino-embryonic antigen is closely related to progressing、staging and diagnosis of lung cancer.This paper aims to explore the application value of five tumor markers in the diagnosis of lung cancer.